Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
Learn more: Enhanced Anticancer Compound May Allow for Precise Activation and Tracking of Treatment
The Latest on: Cancer treatment
[google_news title=”” keyword=”cancer treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer treatment
- Bristol Myers Squibb Cancer-Treatment Trial Misses Endpointon May 10, 2024 at 1:55 pm
Bristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its primary endpoint.
- Dogma-challenging telomere findings may offer new insights for cancer treatmentson May 10, 2024 at 11:39 am
A new study shows that an enzyme called PARP1 is involved in repair of telomeres, the lengths of DNA that protect the tips of chromosomes, and that impairing this process can lead to telomere ...
- Racial, ethnic differences seen in breast cancer treatment declinationon May 10, 2024 at 9:07 am
For patients with breast cancer, there are racial and ethnic differences in treatment declination, according to a study published online May 9 in JAMA Network Open.
- Standard blood cancer treatment reveals positive results in those over 80, study findson May 10, 2024 at 1:11 am
The standard treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, a study published Thursday in Blood Neoplasia finds. The treatment can extend survival for about 25% ...
- The doctor behind the next big thing in cancer treatmenton May 9, 2024 at 10:36 am
Dr Catherine Wu’s research has laid the scientific foundation for the development of cancer vaccines that are tailored to the genetic makeup of an individual’s tumor. It’s a strategy that is looking ...
- The Future of Antibody-Drug Conjugates in Lung Cancer Treatmenton May 9, 2024 at 6:52 am
Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.
- King Charles Takes on First Solo Engagement Since Returning to Royal Duties During Cancer Treatmenton May 9, 2024 at 5:46 am
King Charles made his first solo engagement since resuming royal duties amid his cancer treatment. The monarch met with the families and staff at the Royal School of Military Engineering.
- Matching Cancer Patients To Trials And Treatments With Triomicson May 9, 2024 at 5:00 am
Triomics has raised $15 million of funding as it moves to commercialise its AI platform for oncologists, hospitals and healthcare providers ...
- I Had Cancer. My Treatment Was Eye-Opening About Addictionon May 9, 2024 at 1:30 am
I've had two different types of cancer in two years and in both instances, I was screened, diagnosed early, and ushered into care.
- Breast Cancer Treatment Disparities Impact Survival Based on Race, Age, Socioeconomicson May 8, 2024 at 5:00 pm
A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, ...
via Bing News